I understood that full PPAR agonists (like Thiazolidinediones) resulted in severe side effects and this is why the switch to exploring partial agonists was made.

But doesn't the partial activation of the receptor produces a reduced effect on the PPAR gamma? How would this help in remediating Type 2 diabetes then?

More Ashley D'Souza's questions See All
Similar questions and discussions